The IR Med deal will be huge. Here are a few recent updates from the Zacks Research Report in November:

IR-Med, Inc. (OTCQB: IRME) is a development stage medical device company that is creating noninvasive devices to detect and measure various biomarkers and molecules in the blood and in
human tissue in real-time without resorting to invasive procedures.
 The company’s primary product under advanced development is called PressureSafe and is used to
detect Pressure Injuries in a non-invasive manner with high accuracy, regardless of patient skin
tone.
 The FDA registration for PressureSafe is relatively straightforward and expedient as the device fall]
under the 510(k) regulatory process because it is considered a safe decision support device.
 Populations around the world are aging due to improvements in healthcare. When combined with
other medical conditions such as obesity, this has resulted in more people needing assistance with
activities of daily living due to decreased mobility which can create the development of Pressure
Injuries.
 The company targets hospitals, nursing homes, and home healthcare operators for use of the
PressureSafe device. The company believes this could be a $600 million revenue opportunity just in
the U.S. alone. The global addressable market could be as high as $2.9 billion.
 The company is also in early stage of developing an otoscope that distinguishes between bacterial
and viral infections as well as a therapeutic drug monitoring device that can detect levels of drugs in
patients without the use of blood tests.